Garenoxacin API (CAS No. 194804-75-6) is a synthetic quinolone antibacterial pharmaceutical active ingredient associated with broad-spectrum anti-infective and respiratory pharmaceutical applications.
Garenoxacin is a des-fluoro(6) quinolone antibacterial agent developed to provide antibacterial activity against susceptible Gram-positive and Gram-negative microorganisms.
Garenoxacin acts by inhibiting bacterial DNA topoisomerase IV and DNA gyrase. These bacterial enzymes are essential for DNA replication and maintenance. Inhibition of these enzymes interferes with bacterial DNA replication and prevents susceptible bacteria from growing and multiplying.
Pharmaceutical companies sourcing Garenoxacin API commonly evaluate assay, HPLC purity, stereochemical identity, related substances, process-related impurities, degradation products, residual solvents, water content, crystalline characteristics, particle size distribution, and batch-to-batch consistency.
Because Garenoxacin contains a defined chiral center, stereochemical identity and chiral purity are important quality considerations during API qualification. Pharmaceutical buyers may evaluate specific rotation, enantiomeric purity, chromatographic purity, process-related impurities, and consistency of the API impurity profile.
Garenoxacin free compound and Garenoxacin Mesilate or Mesylate Hydrate should be treated as separate pharmaceutical material identities. Procurement, quality, and regulatory teams should confirm the exact required chemical form before commercial sourcing.
Swapnroop Drugs and Pharmaceuticals supplies Garenoxacin API for qualified pharmaceutical research, formulation development, analytical, antibacterial drug development, and regulated manufacturing requirements with product-specific quality documentation, pharmaceutical-grade packaging, and reliable supply-chain coordination.
Pharmaceutical companies evaluating Garenoxacin API commonly focus on:
Stereochemical consistency is particularly important for Garenoxacin API because the molecule contains a defined R-configuration.
Impurity-profile control is also an important API qualification consideration. Process-related impurities, degradation products, residual solvents, and enantiomeric impurities should be evaluated according to the approved product specification and applicable regulatory requirements.
Garenoxacin API is primarily associated with:
Garenoxacin-related pharmaceutical products have been evaluated for susceptible bacterial infections, particularly respiratory and other anti-infective applications.
Garenoxacin is a synthetic quinolone antibacterial compound associated with inhibition of bacterial DNA replication.
Pharmaceutical formulation companies evaluating Garenoxacin API may review:
Product-specific API specifications should be evaluated according to the intended dosage form, target regulatory market, formulation technology, and approved pharmaceutical development requirements.
Garenoxacin targets bacterial DNA topoisomerase IV and DNA gyrase.
These enzymes are required for bacterial DNA replication, chromosome separation, and maintenance of DNA topology.
Inhibition of bacterial topoisomerase activity interferes with DNA replication and bacterial cell multiplication.
The dual targeting of DNA gyrase and topoisomerase IV is an important pharmacological characteristic of Garenoxacin and other quinolone-class antibacterial compounds.
Garenoxacin and Garenoxacin Mesilate Hydrate should be treated as separate pharmaceutical material identities.
Garenoxacin free compound has CAS No. 194804-75-6, molecular formula C23H20F2N2O4, and molecular weight approximately 426.4 g/mol.
Garenoxacin Mesilate Hydrate is a mesilate salt hydrate form associated with marketed pharmaceutical products in Japan.
Procurement, formulation, quality, and regulatory teams should confirm the exact free compound, mesilate, mesylate, or hydrate form before commercial sourcing.
Swapnroop Drugs and Pharmaceuticals supports qualified pharmaceutical and research customers with:
Garenoxacin API is supplied in secure pharmaceutical-grade packaging selected according to product quantity, stability requirements, moisture protection requirements, and customer specifications.
Product-appropriate inner polyethylene liners and approved pharmaceutical-grade outer containers or HDPE drums may be used according to the supplied material specification.
Available packaging configurations may include:
Packaging configuration, MOQ, commercial quantity, particle size requirements, and shipment conditions are confirmed according to the approved product specification and customer enquiry.
Store Garenoxacin API in tightly closed and appropriately labeled containers under the controlled storage conditions specified in the approved product documentation.
Protect the material from excessive moisture, heat, direct light, and unsuitable environmental exposure.
Handling should be performed by trained personnel using approved pharmaceutical raw material handling procedures and applicable safety documentation.
Product-specific storage and handling requirements should be confirmed from the approved COA, SDS, specification, and stability documentation.
Swapnroop Drugs and Pharmaceuticals provides Garenoxacin API bulk supply and export support in India for qualified pharmaceutical manufacturers, antibacterial formulation developers, generic drug companies, analytical laboratories, research organizations, and pharmaceutical procurement customers.
For Garenoxacin API price, CAS No. 194804-75-6, specification, HPLC purity, chiral purity, related substance profile, COA availability, MOQ, packaging, and export enquiries, contact our pharmaceutical sales team.
Get Bulk Quote via WhatsApp